STAT3 and diffuse large B-cell lymphoma: Chidamide, a new HDAC inhibitor, could be a potent therapeutic agent to treat DLBCL by inducing the DLBCL cell apoptosis by inhibiting the HDACs/STAT3/Bcl‐2 pathway.8